Oxurion enrolls first patient in clinical trial evaluating DME therapy

The first patient has been enrolled in a phase 1 clinical trial to evaluate the safety of a single intravitreal injection of THR-687 in the treatment of diabetic macular edema, according to a press release from Oxurion.

The open-label, multicenter, dose-escalation study will assess the safety of intravitreal injections of escalating dose levels of THR-687 in a maximum of 18 patients with DME.

THR-687 is a novel pan-RGD integrin antagonist that has been demonstrated in preclinical studies to target multiple aspects of retinal vascular disease, such as vessel leakage, inflammation and neovascularization, the release said.

“We are very excited about the progress we have made in advancing THR-687 into the clinic. This is an important step in the clinical development of THR-687 and in establishing the safety profile of this pan integrin antagonist in patients with DME,” Patrik De Haes, MD, CEO of Oxurion, said in the release.

The first patient has been enrolled in a phase 1 clinical trial to evaluate the safety of a single intravitreal injection of THR-687 in the treatment of diabetic macular edema, according to a press release from Oxurion.

The open-label, multicenter, dose-escalation study will assess the safety of intravitreal injections of escalating dose levels of THR-687 in a maximum of 18 patients with DME.

THR-687 is a novel pan-RGD integrin antagonist that has been demonstrated in preclinical studies to target multiple aspects of retinal vascular disease, such as vessel leakage, inflammation and neovascularization, the release said.

“We are very excited about the progress we have made in advancing THR-687 into the clinic. This is an important step in the clinical development of THR-687 and in establishing the safety profile of this pan integrin antagonist in patients with DME,” Patrik De Haes, MD, CEO of Oxurion, said in the release.